Recursion Pharmaceuticals (RXRX) Enterprise Value (2020 - 2026)

Recursion Pharmaceuticals has reported Enterprise Value for 7 years, with the latest figure at -$660.0 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 31.07% year-over-year to -$660.0 million; the trailing twelve-month figure through Mar 2026 stood at -$660.0 million (down 31.07% YoY), and the FY2025 full-year result was -$747.9 million, down 25.19% from the prior year.
• Enterprise Value for Q1 2026 stood at -$660.0 million, up from -$747.9 million in the prior quarter.
• The five-year high for Enterprise Value was -$299.5 million in Q1 2024, with the low at -$747.9 million in Q4 2025.
• Historically, Enterprise Value has averaged -$502.7 million across 5 years, with a median of -$476.1 million in 2024.
• Annual changes were most pronounced in 2022 — Enterprise Value plunged 132.47% — and 2024, when it surged 36.87%.
• Recursion Pharmaceuticals' Enterprise Value stood at -$551.2 million in 2022, then rose by 28.37% to -$394.8 million in 2023, then slumped by 51.32% to -$597.4 million in 2024, then dropped by 25.19% to -$747.9 million in 2025, then increased by 11.75% to -$660.0 million in 2026.
• The last three Enterprise Value figures came in at -$660.0 million (Q1 2026), -$747.9 million (Q4 2025), and -$663.0 million (Q3 2025), per Business Quant data.